Bank of Montreal Can Sells 15,720 Shares of Henry Schein, Inc. $HSIC

Bank of Montreal Can cut its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 14.2% in the 2nd quarter, Holdings Channel reports. The firm owned 95,131 shares of the company’s stock after selling 15,720 shares during the period. Bank of Montreal Can’s holdings in Henry Schein were worth $6,949,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. ANTIPODES PARTNERS Ltd purchased a new position in shares of Henry Schein during the second quarter valued at about $43,000. Steph & Co. bought a new stake in Henry Schein during the 2nd quarter valued at approximately $44,000. CX Institutional grew its holdings in shares of Henry Schein by 107.3% during the 2nd quarter. CX Institutional now owns 651 shares of the company’s stock worth $48,000 after acquiring an additional 337 shares during the period. TD Private Client Wealth LLC raised its position in shares of Henry Schein by 103.0% in the 2nd quarter. TD Private Client Wealth LLC now owns 668 shares of the company’s stock worth $49,000 after acquiring an additional 339 shares in the last quarter. Finally, Whittier Trust Co. raised its position in shares of Henry Schein by 714.3% in the 1st quarter. Whittier Trust Co. now owns 798 shares of the company’s stock worth $55,000 after acquiring an additional 700 shares in the last quarter. 96.62% of the stock is owned by hedge funds and other institutional investors.

Henry Schein Stock Performance

Shares of Henry Schein stock opened at $71.90 on Monday. Henry Schein, Inc. has a 1 year low of $60.56 and a 1 year high of $82.49. The firm’s 50-day moving average is $66.30 and its 200 day moving average is $68.76. The stock has a market cap of $8.46 billion, a price-to-earnings ratio of 23.19, a PEG ratio of 2.06 and a beta of 0.84. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 0.78.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.11. The business had revenue of $3.34 billion during the quarter, compared to analysts’ expectations of $3.28 billion. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. Sell-side analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on HSIC shares. JPMorgan Chase & Co. upped their price target on Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Henry Schein in a research report on Friday, October 31st. Leerink Partners set a $75.00 price target on shares of Henry Schein in a research note on Monday, July 14th. UBS Group dropped their price objective on shares of Henry Schein from $75.00 to $70.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 6th. Finally, Wells Fargo & Company upped their price objective on shares of Henry Schein from $70.00 to $76.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 5th. Five analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $76.08.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.